Profile Image

Dr Roger Liang

Senior Lecturer

School of Biomedical Sciences and Pharmacy (Pharmacy and Experimental Pharmacology)

Career Summary

Biography

Dr Liang was trained as a pharmaceutical scientist and has since developed well-equipped research capabilities and leadership in the cross-disciplinary field of advanced drug delivery and nanomedicine. Dr. Liang completed his PhD in Pharmacy from the University of Queensland. His doctoral research theme was to develop nanoparticulate delivery systems for subunit vaccines, which spanned a range of fields including medicinal chemistry, pharmaceutical formulation, and immunology. Toward the end of his PhD, Dr Liang started to engage in research at the interface between polymer science and drug delivery and had gained hands-on experience in a variety of polymerisation and bioconjugation techniques. Upon completion of PhD, Dr Liang took up a postdoctoral position at UQ to investigate the biological interactions and toxicity of precisely engineered nanoparticles. This research had led to some key fundamental discoveries that resulted in several publications in the premium journals including ACS Nano, Nature Nanotechnology, Nanomedicines etc. During this time, Dr Liang was also a research teaching academic at School of Pharmacy and committed to teaching pharmacy undergraduates. After that, Dr Liang joined the Centre for Advanced Macromolecular Design in University of New South Wales, and his research was to develop a platform technology for the efficient delivery of albendazole towards better anti-cancer treatment. In 2011, Dr Liang accepted a lecturer position to establish drug delivery research group at the School of Biomedical Science and Pharmacy in University of Newcastle.

Research Expertise
Dr Liang’s current research centres on advanced drug delivery and nanomedicine, which are at the interface of multidisciplinary fields including chemical & molecular engineering, materials science, chemistry, biotechnology and medicine. His research mainly involves developing novel biomaterials, utilizing self-assembly strategies to formulate biomaterials into desired nano-, micro- and macroscopic structures, and studying applications of these engineered structures for disease treatment and diagnosis.

Teaching Expertise
I mainly teach into pharmaceutics and pharmacy practice within Master of Pharmacy program. In addition, I also deliver guest lectures into Bachelor of Biomedical Science program in the field of drug delivery.





Qualifications

  • PhD, University of Queensland

Keywords

  • Biomaterials
  • Drug delivery
  • Nanomedicine
  • Pharmaceutics
  • Pharmacy Practice

Fields of Research

Code Description Percentage
320604 Nanomedicine 40
321402 Clinical pharmacology and therapeutics 60

Professional Experience

UON Appointment

Title Organisation / Department
Senior Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (41 outputs)

Year Citation Altmetrics Link
2024 Santhanes D, Zhang H, Wilkins A, Aitken RJ, Gannon A-L, Liang M, 'Precise control of microfluidic flow conditions is critical for harnessing the in vitro transfection capability of pDNA-loaded lipid-Eudragit nanoparticles.', Drug Deliv Transl Res, (2024) [C1]
DOI 10.1007/s13346-024-01523-y
Co-authors John Aitken, Annelouise Gannon
2023 Baldelli A, Liang M, 'Design of respirable sprayed microparticles of encapsulated bacteriophages', Frontiers in Drug Delivery, 3 [C1]
DOI 10.3389/fddev.2023.1209534
2023 Mohanan S, Sathish CI, Ramadass K, Liang M, Vinu A, 'Design and Synthesis of Cabazitaxel Loaded Core-Shell Mesoporous Silica Nanoparticles with Different Morphologies for Prostate Cancer Therapy', Small, [C1]
DOI 10.1002/smll.202303269
Citations Scopus - 2
Co-authors Kavitha Ramadass, Ajayan Vinu, Sathish Ci
2023 Al-Theyab NS, Abuelizz HA, Al-Hamoud GA, Aldossary A, Liang M, 'Priestia megaterium Metabolism: Isolation, Identification of Naringenin Analogues and Genes Elevated Associated with Nanoparticle Intervention', Current Issues in Molecular Biology, 45 6704-6716 [C1]
DOI 10.3390/cimb45080424
2023 Al-Theyab N, Alrasheed O, Abuelizz HA, Liang M, 'Draft genome sequence of potato crop bacterial isolates and nanoparticles-intervention for the induction of secondary metabolites biosynthesis', Saudi Pharmaceutical Journal, 31 783-794 (2023) [C1]
DOI 10.1016/j.jsps.2023.04.016
Citations Scopus - 1
2023 Mohanan S, Guan X, Liang M, Karakoti A, Vinu A, 'Stimuli-Responsive Silica Silanol Conjugates: Strategic Nanoarchitectonics in Targeted Drug Delivery.', Small, e2301113 (2023) [C1]
DOI 10.1002/smll.202301113
Citations Scopus - 8
Co-authors Ajayan Vinu
2023 Mohanan S, Sathish CI, Adams TJ, Kan S, Liang M, Vinu A, 'A Dual Protective Drug Delivery System Based on Lipid Coated Core-Shell Mesoporous Silica for Efficient Delivery of Cabazitaxel to Prostate Cancer Cells', Bulletin of the Chemical Society of Japan, 96 1188-1195 (2023) [C1]
DOI 10.1246/bcsj.20230167
Citations Scopus - 1
Co-authors Ajayan Vinu, Sathish Ci, Thomas Adams Uon
2022 Gao H, Kan S, Ye Z, Feng Y, Jin L, Zhang X, et al., 'Development of in silico methodology for siRNA lipid nanoparticle formulations', Chemical Engineering Journal, 442 (2022) [C1]
DOI 10.1016/j.cej.2022.136310
Citations Scopus - 5Web of Science - 4
Co-authors Xu Zhang, Yuchen Feng, Lei Jin
2022 Santhanes D, Wilkins A, Zhang H, John Aitken R, Liang M, 'Microfluidic formulation of lipid/polymer hybrid nanoparticles for plasmid DNA (pDNA) delivery', International Journal of Pharmaceutics, 627 122223-122223 (2022) [C1]
DOI 10.1016/j.ijpharm.2022.122223
Citations Scopus - 10Web of Science - 2
Co-authors John Aitken
2022 Kan S, Grainge C, Nichol K, Reid A, Knight D, Sun Y, et al., 'TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells', INTERNATIONAL JOURNAL OF PHARMACEUTICS, 617 (2022) [C1]
DOI 10.1016/j.ijpharm.2022.121586
Citations Scopus - 1
Co-authors Darryl Knight, Christopher Grainge, Nathan Bartlett, Andrew Reid
2021 Fraser B, Peters AE, Sutherland JM, Liang M, Rebourcet D, Nixon B, Aitken RJ, 'Biocompatible Nanomaterials as an Emerging Technology in Reproductive Health; a Focus on the Male', Frontiers in Physiology, 12 (2021) [C1]

A growing body of research has confirmed that nanoparticle (NP) systems can enhance delivery of therapeutic and imaging agents as well as prevent potentially damaging systemic exp... [more]

A growing body of research has confirmed that nanoparticle (NP) systems can enhance delivery of therapeutic and imaging agents as well as prevent potentially damaging systemic exposure to these agents by modifying the kinetics of their release. With a wide choice of NP materials possessing different properties and surface modification options with unique targeting agents, bespoke nanosystems have been developed for applications varying from cancer therapeutics and genetic modification to cell imaging. Although there remain many challenges for the clinical application of nanoparticles, including toxicity within the reproductive system, some of these may be overcome with the recent development of biodegradable nanoparticles that offer increased biocompatibility. In recognition of this potential, this review seeks to present recent NP research with a focus on the exciting possibilities posed by the application of biocompatible nanomaterials within the fields of male reproductive medicine, health, and research.

DOI 10.3389/fphys.2021.753686
Citations Scopus - 3
Co-authors John Aitken, Brett Nixon, Diane Rebourcet, Jessie Sutherland
2020 Chen E, Han S, Song B, Xu L, Yuan H, Liang M, Sun Y, 'Mechanism investigation of hyaluronidase-combined multistage nanoparticles for solid tumor penetration and antitumor effect', International Journal of Nanomedicine, 15 6311-6324 (2020) [C1]

Background: Hyaluronic acid (HA) is a major component of extracellular matrix (ECM) and its over expression in tumor tissues contributes to the increase of interstitial fluid pres... [more]

Background: Hyaluronic acid (HA) is a major component of extracellular matrix (ECM) and its over expression in tumor tissues contributes to the increase of interstitial fluid pressure (IFP) and hinders the penetration of nanoparticles into solid tumors. Materials and Methods: We here reported a tumoral microenvironment responsive multi-stage drug delivery system (NPs-EPI/HAase) which was formed layer by layer via electrostatic interaction with epirubicin (EPI)-loaded PEG-b-poly(2-(diisopropylamino)ethyl methacrylate)-b-poly(2-guanidinoethylmethacrylate) (mPEG-PDPA-PG, PEDG) micelles (NPs-EPI) and hyaluronidase (HAase). In this paper, we focused on the hyaluronidase-combined nanoparticles (NPs-EPI/HAase) for tumor penetration in tumor spheroid and solid tumor models in vitro and in vivo. Results: Our results showed that NPs-EPI/HAase effectively degrade the HA in ECM and facilitate deep penetration of NPs-EPI into solid tumor. Moreover, NPs-EPI mainly employed clathrin-mediated and macropinocytosis-mediated endocytic pathways for cellular uptake and were subsequently directed to the lysosomes for further drug release triggered by proton sponge effect. Compared with NPs-EPI, the HAase coating group showed an enhanced tumoral drug delivery efficacy and inhibition of tumor growth. Conclusion: Overall, our studies demonstrated that coating nanoparticles with HAase can provide a simple but efficient strategy for nano-drug carriers to enhance solid tumor penetration and chemotherapeutic efficacy.

DOI 10.2147/IJN.S257164
Citations Scopus - 19Web of Science - 12
2020 Kan S, Hariyadi DM, Grainge C, Knight DA, Bartlett NW, Liang M, 'Airway epithelial-targeted nanoparticles for asthma therapy', AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 318 L500-L509 (2020) [C1]
DOI 10.1152/ajplung.00237.2019
Citations Scopus - 25Web of Science - 13
Co-authors Christopher Grainge, Nathan Bartlett, Darryl Knight
2019 Du C, Liang Y, Ma Q, Sun Q, Qi J, Cao J, et al., 'Intracellular tracking of drug release from pH-sensitive polymeric nanoparticles via FRET for synergistic chemo-photodynamic therapy', JOURNAL OF NANOBIOTECHNOLOGY, 17 (2019) [C1]
DOI 10.1186/s12951-019-0547-2
Citations Scopus - 24Web of Science - 21
2019 Ge R, Cao J, Chi J, Han S, Liang Y, Xu L, et al., 'NIR-guided dendritic nanoplatform for improving antitumor efficacy by combining chemo-phototherapy', International Journal of Nanomedicine, Volume 14 4931-4947 (2019) [C1]
DOI 10.2147/ijn.s203171
Citations Scopus - 25Web of Science - 16
2017 Shargh VH, Hondermarck H, Liang M, 'Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy', Nanomedicine, 12 977-989 (2017) [C1]

Aim: To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA) inhibitor GNF-5837 (Gel-Alb... [more]

Aim: To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA) inhibitor GNF-5837 (Gel-Alb-GNF HNPs) and to demonstrate their anticancer effects in breast cancer. Methods: Gel-Alb-GNF HNPs were prepared using a pH-controlled complexation process from cationic gelatin, dextran sulfate and albumin-bound GNF-5837. The anticancer activities of Gel-Alb-GNF HNPs were tested in a panel of subtype-specific breast cancer cell lines. Results: Gel-Alb-GNF HNPs (~130 nm) displayed excellent stability and matrix metalloproteinase-triggered drug release. Compared with GNF-5837 alone, Gel-Alb-GNF HNPs not only significantly enhanced the antiproliferative and anti-invasive effects but also restored the apoptosis of cancer cells. Conclusion: Gel-Alb-GNF HNPs may be adaptable for stand-alone therapies or used in combination with traditional chemotherapies for breast cancer treatment.

DOI 10.2217/nnm-2016-0419
Citations Scopus - 15Web of Science - 15
Co-authors Hubert Hondermarck
2016 Shargh VH, Hondermarck H, Liang M, 'Antibody-targeted biodegradable nanoparticles for cancer therapy', Nanomedicine, 11 63-79 (2016) [C1]

The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) have been developed for targe... [more]

The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) have been developed for targeted delivery of diagnostic/therapeutic agents to the tumor sites, which thus result in greater efficacy and much less side effects. The targeting property of NPs is often achieved by functionalizing their surface with tumor-specific ligands, such as antibodies, peptides, small molecules and oligonucleotides. In this review, we will discuss recent progress in the multifunctional design of antibody-targeted NPs with a special focus on liposomal, polymeric and protein-based delivery systems.

DOI 10.2217/nnm.15.186
Citations Scopus - 77Web of Science - 62
Co-authors Hubert Hondermarck
2016 Shargh VH, Hondermarck H, Liang M, 'Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.', Int J Pharm, 515 527-534 (2016) [C1]
DOI 10.1016/j.ijpharm.2016.10.057
Citations Scopus - 7Web of Science - 7
Co-authors Hubert Hondermarck
2015 Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL, 'Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model', Journal of Nanobiotechnology, 13 (2015) [C1]
DOI 10.1186/s12951-015-0082-8
Citations Scopus - 81Web of Science - 64
2014 Jiang Y, Liang M, Svejkar D, Hart-Smith G, Lu H, Scarano W, Stenzel MH, 'Albumin-micelles via a one-pot technology platform for the delivery of drugs', Chemical Communications, 50 6394-6394 (2014) [C1]
DOI 10.1039/c4cc00616j
Citations Scopus - 43Web of Science - 40
2014 Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M, 'Albendazole loaded albumin nanoparticles for ovarian cancer therapy', European Journal of Nanomedicine, 6 227-236 (2014) [C1]

Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ l... [more]

Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ limits its use as a systemic anticancer agent. To enable systemic administration, we have formulated ABZ into albumin nanoparticles with a size range of 200-300 nm, which were cross-linked with glutaraldehyde to stabilize the nanoparticles and to introduce pH-responsive features. Drug release studies demonstrated that about 20% of ABZ was released at neutral pH within a week in comparison to 70% at slightly acidic condition (pH 5). Cellular uptake studies using ovarian cancer cells indicated that nanoparticles were internalized efficiently within 1 h of incubation. Further, cell proliferation results demonstrated that albumin nanoparticles alone showed no cytotoxicity to both normal and cancer cells. In contrast, the drug-loaded nanoparticles exhibited cellular toxicity and high killing efficacy to cancer cells compared to normal cells. Collectively, our results suggest that these albumin nanoparticles may hold great potentials as ABZ carriers for cancer therapy.

DOI 10.1515/ejnm-2014-0026
Citations Scopus - 16Web of Science - 13
2013 Deng ZJ, Liang M, Toth I, Monteiro M, Minchin RF, 'Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses', Nanotoxicology, 7 314-322 (2013) [C1]
DOI 10.3109/17435390.2012.655342
Citations Scopus - 124Web of Science - 103
2012 Yhaya F, Sutinah A, Gregory AM, Liang M, Stenzel MH, 'RAFT polymerization of vinyl methacrylate and subsequent conjugation via enzymatic thiol-ene chemistry', Journal of Polymer Science Part A: Polymer Chemistry, 50 4085-4093 (2012) [C1]
Citations Scopus - 13Web of Science - 13
2012 Lin I-C, Liang M, Liu T-Y, Jia Z, Monteiro M, Toth I, 'Effect of polymer grafting density on silica nanoparticle toxicity', Bioorganic and Medicinal Chemistry, 20 6862-6869 (2012) [C1]
Citations Scopus - 17Web of Science - 15
2012 Lin I-C, Liang M, Liu T-Y, Monteiro MJ, Toth I, 'Cellular transport pathways of polymer coated gold nanoparticles', Nanomedicine: Nanotechnology Biology and Medicine, 8 8-11 (2012) [C1]
DOI 10.1016/j.nano.2011.09.014
Citations Scopus - 45Web of Science - 33
2012 Deng ZJ, Liang M, Toth I, Monteiro MJ, Minchin RF, 'Molecular Interaction of Poly(acrylic acid) Gold Nanoparticles with Human Fibrinogen', ACS Nano, 6 8962-8969 (2012) [C1]
DOI 10.1021/nn3029953
Citations Scopus - 173Web of Science - 154
2011 Lin I-C, Liang M, Liu T-Y, Ziora ZM, Monteiro MJ, Toth I, 'Interaction of Densely Polymer-Coated Gold Nanoparticles with Epithelial Caco-2 Monolayers', Biomacromolecules, 12 1339-1348 (2011) [C1]
DOI 10.1021/bm200116z
Citations Scopus - 57Web of Science - 51
2011 Deng ZJ, Liang M, Monteiro MJ, Toth I, Minchin RF, 'Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation', Nature Nanotechnology, 6 39-44 (2011) [C1]
DOI 10.1038/nnano.2010.250
Citations Scopus - 762Web of Science - 664
2011 Yhaya F, Lim J, Kim Y, Liang M, Gregory AM, Stenzel MH, 'Development of Micellar Novel Drug Carrier Utilizing Temperature-Sensitive Block Copolymers Containing Cyclodextrin Moieties', Macromolecules, 44 8433-8445 (2011) [C1]
DOI 10.1021/ma2013964
Citations Scopus - 60Web of Science - 59
2010 Liang M, Lin I-C, Whittaker MR, Minchin RF, Monteiro MJ, Toth I, 'Cellular uptake of densely packed polymer coatings on gold nanoparticles', ACS Nano, 4 403-413 (2010) [C1]
Citations Scopus - 163Web of Science - 149
2009 Wu SY, Putral LN, Liang M, Chang H-I, Davies NM, McMillan NAJ, '. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use', Pharmaceutical Research, 26 512-522 (2009) [C1]
Citations Scopus - 61Web of Science - 53
2008 Sarpietro MG, Micieli D, Pignatello R, Liang M, Toth I, Castelli F, 'Effect of variation in the chain number and length in modulating the interaction of immunogenic lipopeptide with biomembrane models', Thermochimica Acta, 471 14-19 (2008) [C1]
Citations Scopus - 5Web of Science - 4
2008 Liang M, Davies NM, Toth I, 'Increasing entrapment of peptides within poly(alkyl cyanoacrylate) nanoparticles prepared by interfacial polymerization of water-in-oil microemulsions', International Journal of Pharmaceutics, 362 141-146 (2008) [C1]
Citations Scopus - 22Web of Science - 14
2008 Koda Y, Liang M, Blanchfield JT, Toth I, 'In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue', International Journal of Pharmaceutics, 356 37-43 (2008) [C1]
Citations Scopus - 21Web of Science - 16
2008 Liang M, Davies NM, Toth I, 'A novel method for preparing immune stimulating complexes (ISCOMs) by hydration of freeze-dried lipid matrix', European Journal of Pharmaceutics and Biopharmaceutics, 68 840-845 (2008) [C1]
Citations Scopus - 8Web of Science - 8
2006 Liang M, Davies NM, Blanchfield JT, Toth I, 'Particulate systems as adjuvants and carriers for peptide and protein antigen', Current Drug Delivery, 3 379-388 (2006) [C1]
Citations Scopus - 62
2005 Liang M, Davies NM, Toth I, 'Encapsulation of lipopeptides within liposomes: Effect of number of lipid chains, chain length and method of liposome preparation', International Journal of Pharmaceutics, 301 247-254 (2005) [C1]
Citations Scopus - 47Web of Science - 38
2002 Wang DX, Liang MT, Tian GJ, Lin H, Liu HQ, 'A facile pathway to synthesize diketopiperazine derivatives', TETRAHEDRON LETTERS, 43 865-867 (2002)
DOI 10.1016/S0040-4039(01)02005-6
Citations Scopus - 41Web of Science - 37
2002 Liang M, Wang DX, 'Concise and efficient synthesis of dehydropeptide analogues from unsaturated 5(4H)-oxazolone', CHINESE CHEMICAL LETTERS, 13 199-200 (2002)
Citations Scopus - 1Web of Science - 1
2002 Liang M, Wang DX, 'Synthesis of 2-amino-3-arylnorbornane-2-carboxylic acid analogues', Chinese Journal of Medicinal Chemistry, 27-30 (2002)
2001 Liang M, Wang DX, 'Progress in the synthesis and application of beta-lactam', CHINESE JOURNAL OF ORGANIC CHEMISTRY, 97-101 (2001)
Citations Scopus - 5Web of Science - 6
Show 38 more journal articles

Conference (5 outputs)

Year Citation Altmetrics Link
2015 Shargh VH, Hondermarck H, Liang M, 'ENHANCING THE EFFICACY OF TYROSINE KINASE INHIBITORS THROUGH BIO-POLYMERIC ALBUMIN HYBRID NANOPARTICLES IN BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Hubert Hondermarck
2014 Shargh VH, Hondermarck H, Liang M, 'MULTIFUNCTIONAL NANOMEDICINES BASED ON ALBUMIN FOR TARGETED BREAST CANCER THERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Hubert Hondermarck
2012 Zhao Y, Liang M, Kim Y, Tan X, Zhang L, Stenzel MH, 'Development of core-crosslinked micelles for drug delivery system', Advanced Materials Research, Hong Kong (2012) [E1]
Citations Scopus - 1Web of Science - 1
2006 Liang MT, Hennessy T, Toth I, Davies NM, Hook S, 'Synthetic lipopeptides formulated in liposomes: Effect on their immune stimulatory capacity in vitro', Proceedings of the 2006 International Conference on Nanoscience and Nanotechnology, ICONN (2006)

Conjugation of antigenic peptides to lipoamino acids (LAA) has been shown to increase the membrane permeability of peptides and protects them from enzymatic degradation, but the r... [more]

Conjugation of antigenic peptides to lipoamino acids (LAA) has been shown to increase the membrane permeability of peptides and protects them from enzymatic degradation, but the resulting LAA-conjugated peptides were poorly soluble in both aqueous and organic solvents. To overcome the formulation issue and to further enhance the bioactivity, lipopeptide constructs (LAA-LCMV 33-41) have been encapsulated within liposomes with high entrapment efficiency. The purpose of this study was to assess the immune stimulatory capacity of these lipopeptides and their liposomal formulations. Because dendritic cells (DCs) play a key role as antigen-presenting cells in immune responses, the in vitro cellular activities of the lipopeptides and their liposomal formulations were tested by measuring the up-regulation of the surface markers CD80, CD86 and MHCII on DCs. We found that conjugation of lipoamino acid with peptide antigen enhanced its immune stimulatory capacity compared with the unmodified peptide. However, encapsulation of lipopeptides within liposomes appears to compromise their immuno-stimulatory capacity at least at a loading of 10%. © 2006 IEEE.

DOI 10.1109/ICONN.2006.340608
2006 Liang MT, Hennessy T, Toth I, Davies NM, Hook S, 'Synthetic lipopeptides formulated in liposomes: effect on their immune stimulatory capacity in vitro', 2006 INTERNATIONAL CONFERENCE ON NANOSCIENCE AND NANOTECHNOLOGY, VOLS 1 AND 2, AUSTRALIA, Brisbane (2006)
Show 2 more conferences

Preprint (1 outputs)

Year Citation Altmetrics Link
2023 Fraser B, Wilkins A, Whiting S, Liang M, Rebourcet D, Nixon B, Aitken RJ, 'Development of peptides for targeting cell ablation agents concurrently to the Sertoli and Leydig cell populations of the testes: an approach to non-surgical sterilization (2023)
DOI 10.1101/2023.09.17.558160
Co-authors John Aitken

Presentation (7 outputs)

Year Citation Altmetrics Link
2016 Liang M, 'Enhanced anticancer activity of tyrosine kinase inhibitor GNF-5837 via tumor responsive gelatinalbumin hybrid nanoparticles', (2016)
2015 Liang M, 'Albumin-dextran-chitosan hybrid nanoparticle enhances the efficacy of tyrosine kinase inhibitor GNF-5837 in breast cancer', (2015)
2015 Liang M, 'Albumin based nanoparticles can increase the efficiency of Trk inhibitor GNF-5837 in breast cancer', (2015)
2015 Liang M, 'Enhancing the Efficacy of Tyrosine Kinase Inhibitors through Bio-Polymeric Albumin Hybrid Nanoparticles in Breast Cancer', (2015)
2014 Liang M, 'Nanoparticle co-delivery of protein inhibitor and siRNA for cancer treatment', (2014)
2014 Liang M, 'Multifunctional nanomedicines based on albumin for targeted breast cancer therapy', (2014)
2012 Liang M, 'Plasma protein binding of polymer-coated gold nanoparticles elicits different biological responses', (2012)
Show 4 more presentations
Edit

Grants and Funding

Summary

Number of grants 16
Total funding $2,499,482

Click on a grant title below to expand the full details for that specific grant.


20233 grants / $693,526

Adrenal-Targeted Nanobiotechnology: A Novel Therapy for Adrenal Disease $488,860

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Anne-Louise Gannon, Mr Akhil Prafulbhai Gajipara, Doctor Roger Liang, Professor Lee Smith
Scheme Ideas Grants
Role Investigator
Funding Start 2023
Funding Finish 2025
GNo G2301143
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON Y

Development of antiviral RNA therapeutics targeting SARS-CoV-2 infection$124,666

Funding body: Department of Health and Aged Care

Funding body Department of Health and Aged Care
Project Team Doctor Roger Liang, Professor Nathan Bartlett, Professor Anthony Kelleher, Dr Chantelle Ahlenstiel, Professor Maria Kavallaris, Professor Philip Hansbro, Professor Daniela Traini, Professor Pall Thordarson, Associate Professor Kathy Petoumenos, A/P Stuart Turville, Cees van Rijin
Scheme MRFF - COVID-19 Treatment Access and Public Health Activities
Role Lead
Funding Start 2023
Funding Finish 2024
GNo G2200959
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

TLR2/6 agonist boosting immunogenicity of tumour-targeting RNAi-based nanomedicines$80,000

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Professor Nathan Bartlett, Doctor Roger Liang, Miss Ellie Doubleday, Dr Anna Galkin
Scheme RNA Future Leaders PhD Program
Role Investigator
Funding Start 2023
Funding Finish 2026
GNo G2200072
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

20221 grants / $206,281

Adrenal-Targeted Nanobiotechnology: A Novel Therapy for Adrenal Disease$206,281

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Lee Smith, Mr Akhil Prafulbhai Gajipara, Doctor Anne-Louise Gannon, Doctor Roger Liang
Scheme Ideas Grants
Role Investigator
Funding Start 2022
Funding Finish 2024
GNo G2100526
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON Y

20211 grants / $95,000

Büchi Nano Spray Dryer B-90 HP for the preparation of nanocomposite dry powders$95,000

Funding body: The University of Newcastle

Funding body The University of Newcastle
Project Team

Associate Professor Nathan Bartlett, Laureate Professor John Aitken, Conjoint Associate Professor Christopher Grainge, Professor Hubert Hondermarck, Professor Ajayan Vinu, Professor Xu Dong Zhang, Professor Lee Smith, Associate Professor Lei Jin

Scheme Strategic Investment in Research Equipment and Infrastructure Award
Role Lead
Funding Start 2021
Funding Finish 2021
GNo
Type Of Funding Internal
Category INTE
UON N

20202 grants / $1,139,811

Development of nanopharmaceutical strategies for the sterilization of domestic cats and dogs$1,134,811

Funding body: Found Animals Foundation Inc

Funding body Found Animals Foundation Inc
Project Team Professor Lee Smith, Professor Lee Smith, Distinguished Emeritus Professor John Aitken, Doctor Roger Liang, Kari (CHJ) Albers-Wolthers, Dr Pamela Brown
Scheme Michelson Grants in Reproductive Biology
Role Investigator
Funding Start 2020
Funding Finish 2022
GNo G1800032
Type Of Funding C3500 – International Not-for profit
Category 3500
UON Y

RNAi nanomedicine for coronavirus infection $5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Nathan Bartlett, Doctor Roger Liang
Scheme Research Grant
Role Investigator
Funding Start 2020
Funding Finish 2020
GNo G2000216
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

20192 grants / $119,000

Microfluidic Nanoparticle Synthesis$114,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team

Roger Liang

Scheme Equipment Grant
Role Lead
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding Internal
Category INTE
UON N

Computational Drug Design$5,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team

Roger Liang, Adam McCluskey

Scheme New Course Initiative Funding
Role Lead
Funding Start 2019
Funding Finish 2019
GNo
Type Of Funding Internal
Category INTE
UON N

20181 grants / $28,000

Therapeutic Targeting of Long Noncoding RNA REG1CP for Colorectal Cancer Treatment$28,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Roger Liang, Associate Professor Lei Jin, Professor Xu Dong Zhang
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1801350
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20172 grants / $140,364

Novel epithelial targets and targeting strategies to prevent asthma exacerbations$136,364

Funding body: Asthma Australia

Funding body Asthma Australia
Project Team Professor Nathan Bartlett, Conjoint Professor Peter Wark, Doctor Roger Liang, Professor Darryl Knight
Scheme National Research Program
Role Investigator
Funding Start 2017
Funding Finish 2018
GNo G1601217
Type Of Funding C3100 – Aust For Profit
Category 3100
UON Y

Nanoparticle-mediated mitochondrial delivery of antioxidants for asthma therapy$4,000

Funding body: Faculty of Health and Medicine, University of Newcastle

Funding body Faculty of Health and Medicine, University of Newcastle
Project Team

Dr Roger Liang, Prof Darryl Knight, Dr Nathan Bartlett, A/P Christopher Grainge

Scheme Strategic Pilot Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo
Type Of Funding Internal
Category INTE
UON N

20152 grants / $31,000

Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Kathryn Skelding, Doctor Mengna Chi, Associate Professor Nikki Verrills, Doctor Roger Liang
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1600224
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

A supramolecular platform toward mitochondria-targeted nanomedicines$6,000

Funding body: Faculty of Health and Medicine, University of Newcastle

Funding body Faculty of Health and Medicine, University of Newcastle
Project Team

Dr Roger Liang

Scheme Faculty Pilot Grant
Role Lead
Funding Start 2015
Funding Finish 2016
GNo
Type Of Funding Internal
Category INTE
UON N

20141 grants / $1,500

4th Annual World Congress of Nanoscience and Technology, Qingdao, P.R.China, 23 - 31 October 2014$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Roger Liang
Scheme Travel Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400985
Type Of Funding Internal
Category INTE
UON Y

20121 grants / $45,000

Novel biomaterials and drug delivery $45,000

Funding body: The Faculty of Health Science / The University of Newcastle / Australia

Funding body The Faculty of Health Science / The University of Newcastle / Australia
Project Team

Dr Roger Liang

Scheme Startup funding
Role Lead
Funding Start 2012
Funding Finish 2013
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Research Supervision

Number of supervisions

Completed7
Current5

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2023 PhD TLR2 Agonist Boosting Immunogenicity of Tumour-Targeting RNAi-Based Nanomedicines PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2022 PhD Adrenal Targeted Nanobiotechnology: Novel Gene Therapy Approach for Adrenal Disease PhD (Biological Sciences), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
2022 PhD Airway Epithelial Cell-Targeting Nanoparticles to Harness RNA Interference Therapeutics for Respiratory Virus Induced Diseases PhD (Immunology & Microbiol), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2022 PhD Cockle Shell-based Calcium Carbonate Aragonite Nanoparticles as Vascular Contrast Agent for Diagnostic and Theranostic Angiography Applications PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2021 PhD Targeting Mitochondrial ROS in Airway Epithelial Cells to Prevent Virus Induced Disease in Asthma and COPD PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2024 PhD Microfluidic-assisted Synthesis and Development of Lipid-polymer Hybrid Nanoparticles for Nucleic Acid Delivery PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2023 PhD Design of Drug Delivery System Based on Stimuli-Responsive Mesoporous Silica Nanoparticles with Core-Shell Structure for Prostate Cancer PhD (Materials Science & Eng), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
2023 PhD Nanoparticle Intervention of Microbial Metabolism for Drug Discovery PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2022 PhD Development of a Novel Injectable Chemical Agent for the Sterilisation of Cats and Dogs PhD (Biological Sciences), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
2021 PhD Development of Airway Epithelial Targeted Nanoparticles Loaded with TLR7 agonist for Asthma Therapy PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
2019 Honours Microfluidic synthesis of functional nanoparticles for biomedical applications Pharmacy, The University of Newcastle Principal Supervisor
2017 PhD Multifunctional Nanomedicines Based on Albumin for Targeted Breast Cancer Therapy PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle Principal Supervisor
Edit

Dr Roger Liang

Position

Senior Lecturer
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Email roger.liang@newcastle.edu.au
Phone (02) 4985 4959
Fax (02) 4921 7903

Office

Room MS117
Building Medical Science Building
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit